What are the symptoms of Hereditary Hemorrhagic Telangiectasia (HHT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Symptoms of Hereditary Hemorrhagic Telangiectasia

Hereditary hemorrhagic telangiectasia presents with recurrent spontaneous nosebleeds (epistaxis) in over 90% of adults, visible telangiectasias on skin and mucous membranes, and potentially life-threatening arteriovenous malformations in internal organs. 1, 2

Primary Clinical Manifestations

Epistaxis (Nosebleeds)

  • Recurrent spontaneous nosebleeds are the hallmark symptom, occurring in more than 90-95% of adults with HHT and typically beginning in childhood around age 11 years 1, 2, 3
  • Epistaxis results from rupture of fragile nasal mucosal telangiectasias and causes significant psychosocial morbidity, social isolation, and difficulties with employment, travel, and routine daily activities 1
  • The bleeding is spontaneous and recurrent, not triggered by trauma, which distinguishes it from ordinary nosebleeds 1

Mucocutaneous Telangiectasias

  • Multiple telangiectasias appear at characteristic sites including lips, oral cavity (especially tongue), fingers, nose, and nail beds 1, 3
  • These lesions present as punctate, linear, or splinter-like red spots on the skin and mucous membranes 3
  • Telangiectasias have age-related expression, becoming more prominent over time 1

Visceral Organ Involvement

Gastrointestinal Manifestations

  • Gastrointestinal telangiectasias cause chronic bleeding leading to melena (blood in stool) and severe iron deficiency anemia 3, 4
  • GI bleeding may be disproportionate to the severity of epistaxis, warranting endoscopic evaluation 1
  • Telangiectasias can develop throughout the GI tract including stomach, duodenum, and colon 3

Pulmonary Arteriovenous Malformations

  • Pulmonary AVMs create right-to-left shunts causing hypoxemia and risk of paradoxical emboli 5, 6
  • These can lead to life-threatening complications including ischemic stroke or cerebral abscess, often occurring asymptomatically before detection 5, 6
  • Pulmonary AVMs are more frequent and larger in HHT type 1 (ENG mutations) compared to type 2 5, 7

Hepatic Involvement

  • Hepatic vascular malformations occur in 44-74% of HHT patients, though only 5-8% become symptomatic 1
  • Symptomatic liver involvement causes high-output heart failure due to left-to-right shunting 6, 4
  • Hepatic AVMs are substantially more common in HHT type 2 (ACVRL1 mutations) with marked female predominance 1

Central Nervous System Manifestations

  • Cerebral and spinal AVMs can cause stroke, cerebral abscess, or hemorrhage 5, 8
  • Nearly one in five HHT patients develop stroke or cerebral abscess from undetected AVMs 5
  • Cerebral AVMs occur more commonly in HHT type 1 1

Systemic Consequences

Anemia and Iron Deficiency

  • Chronic bleeding from epistaxis and GI telangiectasias leads to severe iron deficiency anemia requiring frequent blood transfusions 3, 4
  • Anemia causes fatigue, palpitations, and can progress to high-output heart failure 4
  • Iron deficiency is often the primary cause of morbidity in adults with HHT 6

Important Clinical Pitfalls

  • Children typically present with isolated epistaxis only, with visceral AVMs developing later, so early screening is essential even without systemic symptoms 1, 6
  • Patients may have asymptomatic but life-threatening AVMs, particularly in the lungs and brain, making screening mandatory regardless of symptoms 5
  • The mean age for hepatic VM presentation is 52 years, indicating symptoms evolve over time and may not be present at initial diagnosis 1
  • SMAD4 mutation carriers may lack overt HHT symptoms but remain at high risk for asymptomatic AVMs and have additional risk of gastric cancer 5

References

Guideline

Diagnostic Approach for Hereditary Hemorrhagic Telangiectasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Autosomal Dominant Bleeding Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Hereditary Hemorrhagic Telangiectasia with ENG and SMAD4 Mutations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hereditary haemorrhagic telangiectasia.

Nature reviews. Disease primers, 2025

Research

Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.

Journal of thrombosis and haemostasis : JTH, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.